PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 14th Israel Controlled Release Society (ICRS) Conference. The company's Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs, Dalit Hazan, will deliver a presentation titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" on September 7, 2025.
The presentation is scheduled for 5:25 PM - 5:45 PM local time at the Enjoy Hotel, Dead Sea, Israel, as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."
PolyPid (Nasdaq: PYPD), azienda biotecnologica in fase avanzata focalizzata sul miglioramento degli esiti chirurgici, ha annunciato la sua partecipazione alla 14ª conferenza della Israel Controlled Release Society (ICRS). Dalit Hazan, Viceamministratore Delegato e EVP di R&S, Clinica e Affari Regolatori, terrà una presentazione intitolata "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" il 7 settembre 2025.
La presentazione è prevista dalle 17:25 alle 17:45 ora locale presso l'Enjoy Hotel, Mar Morto, Israele, e farà parte della Sessione 1 su "Progressi nella somministrazione mirata e controllata di farmaci".
PolyPid (Nasdaq: PYPD), una compañía biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado su participación en la 14.ª Conferencia de la Israel Controlled Release Society (ICRS). Dalit Hazan, directora adjunta y EVP de I+D, Clínico y Asuntos Regulatorios, ofrecerá una presentación titulada "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" el 7 de septiembre de 2025.
La presentación está programada de 17:25 a 17:45 hora local en el Enjoy Hotel, Mar Muerto, Israel, como parte de la Sesión 1 sobre "Avances en la liberación dirigida y controlada de fármacos".
PolyPid (Nasdaq: PYPD), 수술 결과 개선에 주력하는 후기 단계 바이오제약 기업이 제14회 이스라엘 제어 방출 학회(ICRS) 학술대회에 참가한다고 발표했습니다. 회사의 부대표 겸 연구개발·임상·규제담당 EVP인 다릿 하잔(Dalit Hazan)이 2025년 9월 7일에 "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial"라는 제목의 발표를 합니다.
발표는 현지 시간으로 오후 5시25분부터 5시45분까지, 사해의 Enjoy Hotel에서 열리는 "표적화 및 제어된 약물 전달의 진전" 세션 1의 일부로 진행됩니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la 14e conférence de l'Israel Controlled Release Society (ICRS). Dalit Hazan, directrice générale adjointe et EVP R&D, clinique et affaires réglementaires, présentera une communication intitulée « Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial » le 7 septembre 2025.
La présentation est prévue de 17h25 à 17h45, heure locale, à l'Enjoy Hotel, Mer Morte, Israël, dans le cadre de la session 1 sur « Progrès en matière d'administration ciblée et contrôlée de médicaments ».
PolyPid (Nasdaq: PYPD), ein Biopharmaunternehmen in der Spätphase, das sich auf die Verbesserung chirurgischer Ergebnisse konzentriert, hat seine Teilnahme an der 14. Konferenz der Israel Controlled Release Society (ICRS) angekündigt. Dalit Hazan, stellvertretende CEO und EVP für F&E, Klinisches und Regulatorische Angelegenheiten, wird am 7. September 2025 einen Vortrag mit dem Titel "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" halten.
Der Vortrag ist für 17:25–17:45 Uhr Ortszeit im Enjoy Hotel, Totes Meer, Israel, geplant und gehört zur Sitzung 1 „Fortschritte in der gezielten und kontrollierten Wirkstofffreisetzung“.
- None.
- None.
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025.
The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on Sunday, September 7, 2025, from 5:25 PM - 5:45 PM local time as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
polypid@arxadvisory.com
FAQ
When and where will PolyPid (PYPD) present at the ICRS Conference 2025?
Who will be presenting for PolyPid at the ICRS Conference 2025?
What is the topic of PolyPid's presentation at the ICRS Conference?
What is PolyPid's (PYPD) main business focus?
